» Articles » PMID: 26762992

Perinatal Outcomes Associated with Maternal HIV Infection: a Systematic Review and Meta-analysis

Overview
Journal Lancet HIV
Date 2016 Jan 15
PMID 26762992
Citations 123
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The HIV pandemic affects 36·9 million people worldwide, of whom 1·5 million are pregnant women. 91% of HIV-positive pregnant women reside in sub-Saharan Africa, a region that also has very poor perinatal outcomes. We aimed to establish whether untreated maternal HIV infection is associated with specific perinatal outcomes.

Methods: We did a systematic review and meta-analysis of the scientific literature by searching PubMed, CINAHL (Ebscohost), Global Health (Ovid), EMBASE (Ovid), and the Cochrane Central Register of Controlled Trials and four clinical trial databases (WHO International Clinical Trials Registry Platform, the Pan African Clinical Trials Registry, the ClinicalTrials.gov database, and the ISRCTN Registry) for studies published from Jan 1, 1980, to Dec 7, 2014. Two authors independently reviewed the studies retrieved by the scientific literature search, identified relevant studies, and extracted the data. We investigated the associations between maternal HIV infection in women naive to antiretroviral therapy and 11 perinatal outcomes: preterm birth, very preterm birth, low birthweight, very low birthweight, term low birthweight, preterm low birthweight, small for gestational age, very small for gestational age, miscarriage, stillbirth, and neonatal death. We included prospective and retrospective cohort studies and case-control studies reporting perinatal outcomes in HIV-positive women naive to antiretroviral therapy and HIV-negative controls. We used a random-effects model for the meta-analyses of specific perinatal outcomes. We did subgroup and sensitivity analyses and assessed the effect of adjustment for confounders. This systematic review and meta-analysis is registered with PROSPERO, number CRD42013005638.

Findings: Of 60,750 studies identified, we obtained data from 35 studies (20 prospective cohort studies, 12 retrospective cohort studies, and three case-control studies) including 53 623 women. Our meta-analyses of prospective cohort studies show that maternal HIV infection is associated with an increased risk of preterm birth (relative risk 1·50, 95% CI 1·24-1·82), low birthweight (1·62, 1·41-1·86), small for gestational age (1·31, 1·14-1·51), and stillbirth (1·67, 1·05-2·66). Retrospective cohort studies also suggest an increased risk of term low birthweight (2·62, 1·15-5·93) and preterm low birthweight (3·25, 2·12-4·99). The strongest and most consistent evidence for these associations is identified in sub-Saharan Africa. No association was identified between maternal HIV infection and very preterm birth, very small for gestational age, very low birthweight, miscarriage, or neonatal death, although few data were available for these outcomes. Correction for confounders did not affect the significance of these findings.

Interpretation: Maternal HIV infection in women who have not received antiretroviral therapy is associated with preterm birth, low birthweight, small for gestational age, and stillbirth, especially in sub-Saharan Africa. Research is needed to assess how antiretroviral therapy regimens affect these perinatal outcomes.

Funding: None.

Citing Articles

Antiretroviral drug exposure in pregnancy and risk of congenital anomalies: a European case/non-case malformed study.

Saint-Lary L, Beau A, Sommet A, Leroy V, Loane M, Cavero-Carbonell C Eur J Clin Pharmacol. 2025; .

PMID: 40011239 DOI: 10.1007/s00228-025-03814-w.


Perinatal outcomes among pregnant women with HIV initiating antiretroviral therapy preconception and antenatally.

Boering P, Murray C, Portwood C, Hey M, Thompson L, Beck K AIDS. 2025; 39(5):584-596.

PMID: 39760703 PMC: 11902611. DOI: 10.1097/QAD.0000000000004104.


Subsequent pregnancies in the IMPAACT 2010/VESTED Trial: high rate of adverse outcomes in women living with HIV.

Fairlie L, Brummel S, Ziemba L, Coletti A, Chinula L, Shapiro R J Acquir Immune Defic Syndr. 2025; 97(2):150-155.

PMID: 39742354 PMC: 11684739. DOI: 10.1097/qai.0000000000003473.


Adverse birth outcome research case definitions associated with maternal HIV and antiretroviral drug use in pregnancy: a scoping review.

Dube K, de Beer S, Powis K, McCaul M, Slogrove A BMC Pregnancy Childbirth. 2024; 24(1):844.

PMID: 39709379 PMC: 11662713. DOI: 10.1186/s12884-024-06939-5.


Role of Dolutegravir/Lamivudine in the Management of Pregnant People Living with HIV-1: A Narrative Review.

Short W, Patel P, Verdier G, Puga A, Vannappagari V, de Ruiter A Infect Dis Ther. 2024; 14(1):59-80.

PMID: 39652285 PMC: 11782740. DOI: 10.1007/s40121-024-01085-z.